- Home
- ARQT vs QLYS Comparison
ARQT vs QLYS Comparison
Compare ARQT & QLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARQT | QLYS |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.2B |
| IPO Year | 2020 | 2012 |
Fundamental Metrics
Financial Performance| Metric | ARQT | QLYS |
|---|---|---|
| Price | $20.69 | $102.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 13 |
| Target Price | $34.00 | ★ $133.08 |
| AVG Volume (30 Days) | ★ 1.9M | 743.2K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.79 | 16.99 |
| EPS | N/A | ★ 1.42 |
| Revenue | ★ $376,072,000.00 | $321,607,000.00 |
| Revenue This Year | $34.85 | $9.97 |
| Revenue Next Year | $29.39 | $7.15 |
| P/E Ratio | ★ N/A | $70.58 |
| Revenue Growth | ★ 91.34 | 15.32 |
| 52 Week Low | $12.72 | $74.51 |
| 52 Week High | $31.77 | $155.47 |
Technical Indicators
Market Signals| Indicator | ARQT | QLYS |
|---|---|---|
| Relative Strength Index (RSI) | 41.95 | 66.78 |
| Support Level | $19.60 | $83.94 |
| Resistance Level | $24.56 | $136.21 |
| Average True Range (ATR) | 1.26 | 4.70 |
| MACD | -0.07 | 1.43 |
| Stochastic Oscillator | 28.34 | 89.71 |
Price Performance
Historical ComparisonAbout ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
About QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.